Summary
According to APO Research, the global Peramivir market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Peramivir is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Peramivir is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Peramivir market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Peramivir is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Peramivir market include BioCryst Pharmaceuticals, Green Cross Pharma, Hikma Pharmaceuticals, Moksha8 Pharma, NeoPharm, NT Pharma, SCOLR Pharma, Hunan Nucien Pharmaceutical Co., Ltd. and Merck, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Peramivir, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Peramivir, also provides the sales of main regions and countries. Of the upcoming market potential for Peramivir, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Peramivir sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Peramivir market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Peramivir sales, projected growth trends, production technology, application and end-user industry.
Peramivir Segment by Company
BioCryst Pharmaceuticals
Green Cross Pharma
Hikma Pharmaceuticals
Moksha8 Pharma
NeoPharm
NT Pharma
SCOLR Pharma
Hunan Nucien Pharmaceutical Co., Ltd.
Merck
Shionogi Co.
Peramivir Segment by Type
Solution
Solid
Peramivir Segment by Application
Influenza A Treatment
Influenza B Treatment
Peramivir Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Peramivir status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Peramivir market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Peramivir significant trends, drivers, influence factors in global and regions.
6. To analyze Peramivir competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peramivir market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peramivir and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peramivir.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Peramivir market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peramivir industry.
Chapter 3: Detailed analysis of Peramivir manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Peramivir in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Peramivir in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
- Market Overview
- Product Definition
- Global Market Growth Prospects
- Global Peramivir Sales Value (2020-2031)
- Global Peramivir Sales Volume (2020-2031)
- Global Peramivir Sales Average Price (2020-2031)
- Assumptions and Limitations
- Study Goals and Objectives
- Peramivir Market Dynamics
- Peramivir Industry Trends
- Peramivir Industry Drivers
- Peramivir Industry Opportunities and Challenges
- Peramivir Industry Restraints
- Peramivir Market by Company
- Global Peramivir Company Revenue Ranking in 2024
- Global Peramivir Revenue by Company (2020-2025)
- Global Peramivir Sales Volume by Company (2020-2025)
- Global Peramivir Average Price by Company (2020-2025)
- Global Peramivir Company Ranking (2023-2025)
- Global Peramivir Company Manufacturing Base and Headquarters
- Global Peramivir Company Product Type and Application
- Global Peramivir Company Establishment Date
- Market Competitive Analysis
- Global Peramivir Market Concentration Ratio (CR5 and HHI)
- Global Top 5 and 10 Company Market Share by Revenue in 2024
- 2024 Peramivir Tier 1, Tier 2, and Tier 3 Companies
- Mergers and Acquisitions Expansion
- Peramivir Market by Type
- Peramivir Type Introduction
- Solution
- Solid
- Global Peramivir Sales Volume by Type
- Global Peramivir Sales Volume by Type (2020 VS 2024 VS 2031)
- Global Peramivir Sales Volume by Type (2020-2031)
- Global Peramivir Sales Volume Share by Type (2020-2031)
- Global Peramivir Sales Value by Type
- Global Peramivir Sales Value by Type (2020 VS 2024 VS 2031)
- Global Peramivir Sales Value by Type (2020-2031)
- Global Peramivir Sales Value Share by Type (2020-2031)
- Peramivir Type Introduction
- Peramivir Market by Application
- Peramivir Application Introduction
- Influenza A Treatment
- Influenza B Treatment
- Global Peramivir Sales Volume by Application
- Global Peramivir Sales Volume by Application (2020 VS 2024 VS 2031)
- Global Peramivir Sales Volume by Application (2020-2031)
- Global Peramivir Sales Volume Share by Application (2020-2031)
- Global Peramivir Sales Value by Application
- Global Peramivir Sales Value by Application (2020 VS 2024 VS 2031)
- Global Peramivir Sales Value by Application (2020-2031)
- Global Peramivir Sales Value Share by Application (2020-2031)
- Peramivir Application Introduction
- Peramivir Regional Sales and Value Analysis
- Global Peramivir Sales by Region: 2020 VS 2024 VS 2031
- Global Peramivir Sales by Region (2020-2031)
- Global Peramivir Sales by Region: 2020-2025
- Global Peramivir Sales by Region (2026-2031)
- Global Peramivir Sales Value by Region: 2020 VS 2024 VS 2031
- Global Peramivir Sales Value by Region (2020-2031)
- Global Peramivir Sales Value by Region: 2020-2025
- Global Peramivir Sales Value by Region (2026-2031)
- Global Peramivir Market Price Analysis by Region (2020-2025)
- North America
- North America Peramivir Sales Value (2020-2031)
- North America Peramivir Sales Value Share by Country, 2024 VS 2031
- Europe
- Europe Peramivir Sales Value (2020-2031)
- Europe Peramivir Sales Value Share by Country, 2024 VS 2031
- Asia-Pacific
- Asia-Pacific Peramivir Sales Value (2020-2031)
- Asia-Pacific Peramivir Sales Value Share by Country, 2024 VS 2031
- South America
- South America Peramivir Sales Value (2020-2031)
- South America Peramivir Sales Value Share by Country, 2024 VS 2031
- Middle East & Africa
- Middle East & Africa Peramivir Sales Value (2020-2031)
- Middle East & Africa Peramivir Sales Value Share by Country, 2024 VS 2031
- Peramivir Country-level Sales and Value Analysis
- Global Peramivir Sales by Country: 2020 VS 2024 VS 2031
- Global Peramivir Sales Value by Country: 2020 VS 2024 VS 2031
- Global Peramivir Sales by Country (2020-2031)
- Global Peramivir Sales by Country (2020-2025)
- Global Peramivir Sales by Country (2026-2031)
- Global Peramivir Sales Value by Country (2020-2031)
- Global Peramivir Sales Value by Country (2020-2025)
- Global Peramivir Sales Value by Country (2026-2031)
- USA
- USA Peramivir Sales Value Growth Rate (2020-2031)
- USA Peramivir Sales Value Share by Type, 2024 VS 2031
- USA Peramivir Sales Value Share by Application, 2024 VS 2031
- Canada
- Canada Peramivir Sales Value Growth Rate (2020-2031)
- Canada Peramivir Sales Value Share by Type, 2024 VS 2031
- Canada Peramivir Sales Value Share by Application, 2024 VS 2031
- Mexico
- Mexico Peramivir Sales Value Growth Rate (2020-2031)
- Mexico Peramivir Sales Value Share by Type, 2024 VS 2031
- Mexico Peramivir Sales Value Share by Application, 2024 VS 2031
- Germany
- Germany Peramivir Sales Value Growth Rate (2020-2031)
- Germany Peramivir Sales Value Share by Type, 2024 VS 2031
- Germany Peramivir Sales Value Share by Application, 2024 VS 2031
- France
- France Peramivir Sales Value Growth Rate (2020-2031)
- France Peramivir Sales Value Share by Type, 2024 VS 2031
- France Peramivir Sales Value Share by Application, 2024 VS 2031
- U.K.
- U.K. Peramivir Sales Value Growth Rate (2020-2031)
- U.K. Peramivir Sales Value Share by Type, 2024 VS 2031
- U.K. Peramivir Sales Value Share by Application, 2024 VS 2031
- Italy
- Italy Peramivir Sales Value Growth Rate (2020-2031)
- Italy Peramivir Sales Value Share by Type, 2024 VS 2031
- Italy Peramivir Sales Value Share by Application, 2024 VS 2031
- Spain
- Spain Peramivir Sales Value Growth Rate (2020-2031)
- Spain Peramivir Sales Value Share by Type, 2024 VS 2031
- Spain Peramivir Sales Value Share by Application, 2024 VS 2031
- Russia
- Russia Peramivir Sales Value Growth Rate (2020-2031)
- Russia Peramivir Sales Value Share by Type, 2024 VS 2031
- Russia Peramivir Sales Value Share by Application, 2024 VS 2031
- Netherlands
- Netherlands Peramivir Sales Value Growth Rate (2020-2031)
- Netherlands Peramivir Sales Value Share by Type, 2024 VS 2031
- Netherlands Peramivir Sales Value Share by Application, 2024 VS 2031
- Nordic Countries
- Nordic Countries Peramivir Sales Value Growth Rate (2020-2031)
- Nordic Countries Peramivir Sales Value Share by Type, 2024 VS 2031
- Nordic Countries Peramivir Sales Value Share by Application, 2024 VS 2031
- China
- China Peramivir Sales Value Growth Rate (2020-2031)
- China Peramivir Sales Value Share by Type, 2024 VS 2031
- China Peramivir Sales Value Share by Application, 2024 VS 2031
- Japan
- Japan Peramivir Sales Value Growth Rate (2020-2031)
- Japan Peramivir Sales Value Share by Type, 2024 VS 2031
- Japan Peramivir Sales Value Share by Application, 2024 VS 2031
- South Korea
- South Korea Peramivir Sales Value Growth Rate (2020-2031)
- South Korea Peramivir Sales Value Share by Type, 2024 VS 2031
- South Korea Peramivir Sales Value Share by Application, 2024 VS 2031
- India
- India Peramivir Sales Value Growth Rate (2020-2031)
- India Peramivir Sales Value Share by Type, 2024 VS 2031
- India Peramivir Sales Value Share by Application, 2024 VS 2031
- Australia
- Australia Peramivir Sales Value Growth Rate (2020-2031)
- Australia Peramivir Sales Value Share by Type, 2024 VS 2031
- Australia Peramivir Sales Value Share by Application, 2024 VS 2031
- Southeast Asia
- Southeast Asia Peramivir Sales Value Growth Rate (2020-2031)
- Southeast Asia Peramivir Sales Value Share by Type, 2024 VS 2031
- Southeast Asia Peramivir Sales Value Share by Application, 2024 VS 2031
- Brazil
- Brazil Peramivir Sales Value Growth Rate (2020-2031)
- Brazil Peramivir Sales Value Share by Type, 2024 VS 2031
- Brazil Peramivir Sales Value Share by Application, 2024 VS 2031
- Argentina
- Argentina Peramivir Sales Value Growth Rate (2020-2031)
- Argentina Peramivir Sales Value Share by Type, 2024 VS 2031
- Argentina Peramivir Sales Value Share by Application, 2024 VS 2031
- Chile
- Chile Peramivir Sales Value Growth Rate (2020-2031)
- Chile Peramivir Sales Value Share by Type, 2024 VS 2031
- Chile Peramivir Sales Value Share by Application, 2024 VS 2031
- Colombia
- Colombia Peramivir Sales Value Growth Rate (2020-2031)
- Colombia Peramivir Sales Value Share by Type, 2024 VS 2031
- Colombia Peramivir Sales Value Share by Application, 2024 VS 2031
- Peru
- Peru Peramivir Sales Value Growth Rate (2020-2031)
- Peru Peramivir Sales Value Share by Type, 2024 VS 2031
- Peru Peramivir Sales Value Share by Application, 2024 VS 2031
- Saudi Arabia
- Saudi Arabia Peramivir Sales Value Growth Rate (2020-2031)
- Saudi Arabia Peramivir Sales Value Share by Type, 2024 VS 2031
- Saudi Arabia Peramivir Sales Value Share by Application, 2024 VS 2031
- Israel
- Israel Peramivir Sales Value Growth Rate (2020-2031)
- Israel Peramivir Sales Value Share by Type, 2024 VS 2031
- Israel Peramivir Sales Value Share by Application, 2024 VS 2031
- UAE
- UAE Peramivir Sales Value Growth Rate (2020-2031)
- UAE Peramivir Sales Value Share by Type, 2024 VS 2031
- UAE Peramivir Sales Value Share by Application, 2024 VS 2031
- Turkey
- Turkey Peramivir Sales Value Growth Rate (2020-2031)
- Turkey Peramivir Sales Value Share by Type, 2024 VS 2031
- Turkey Peramivir Sales Value Share by Application, 2024 VS 2031
- Iran
- Iran Peramivir Sales Value Growth Rate (2020-2031)
- Iran Peramivir Sales Value Share by Type, 2024 VS 2031
- Iran Peramivir Sales Value Share by Application, 2024 VS 2031
- Egypt
- Egypt Peramivir Sales Value Growth Rate (2020-2031)
- Egypt Peramivir Sales Value Share by Type, 2024 VS 2031
- Egypt Peramivir Sales Value Share by Application, 2024 VS 2031
- Company Profiles
- BioCryst Pharmaceuticals
- BioCryst Pharmaceuticals Comapny Information
- BioCryst Pharmaceuticals Business Overview
- BioCryst Pharmaceuticals Peramivir Sales, Value and Gross Margin (2020-2025)
- BioCryst Pharmaceuticals Peramivir Product Portfolio
- BioCryst Pharmaceuticals Recent Developments
- Green Cross Pharma
- Green Cross Pharma Comapny Information
- Green Cross Pharma Business Overview
- Green Cross Pharma Peramivir Sales, Value and Gross Margin (2020-2025)
- Green Cross Pharma Peramivir Product Portfolio
- Green Cross Pharma Recent Developments
- Hikma Pharmaceuticals
- Hikma Pharmaceuticals Comapny Information
- Hikma Pharmaceuticals Business Overview
- Hikma Pharmaceuticals Peramivir Sales, Value and Gross Margin (2020-2025)
- Hikma Pharmaceuticals Peramivir Product Portfolio
- Hikma Pharmaceuticals Recent Developments
- Moksha8 Pharma
- Moksha8 Pharma Comapny Information
- Moksha8 Pharma Business Overview
- Moksha8 Pharma Peramivir Sales, Value and Gross Margin (2020-2025)
- Moksha8 Pharma Peramivir Product Portfolio
- Moksha8 Pharma Recent Developments
- NeoPharm
- NeoPharm Comapny Information
- NeoPharm Business Overview
- NeoPharm Peramivir Sales, Value and Gross Margin (2020-2025)
- NeoPharm Peramivir Product Portfolio
- NeoPharm Recent Developments
- NT Pharma
- NT Pharma Comapny Information
- NT Pharma Business Overview
- NT Pharma Peramivir Sales, Value and Gross Margin (2020-2025)
- NT Pharma Peramivir Product Portfolio
- NT Pharma Recent Developments
- SCOLR Pharma
- SCOLR Pharma Comapny Information
- SCOLR Pharma Business Overview
- SCOLR Pharma Peramivir Sales, Value and Gross Margin (2020-2025)
- SCOLR Pharma Peramivir Product Portfolio
- SCOLR Pharma Recent Developments
- Hunan Nucien Pharmaceutical Co., Ltd.
- Hunan Nucien Pharmaceutical Co., Ltd. Comapny Information
- Hunan Nucien Pharmaceutical Co., Ltd. Business Overview
- Hunan Nucien Pharmaceutical Co., Ltd. Peramivir Sales, Value and Gross Margin (2020-2025)
- Hunan Nucien Pharmaceutical Co., Ltd. Peramivir Product Portfolio
- Hunan Nucien Pharmaceutical Co., Ltd. Recent Developments
- Merck
- Merck Comapny Information
- Merck Business Overview
- Merck Peramivir Sales, Value and Gross Margin (2020-2025)
- Merck Peramivir Product Portfolio
- Merck Recent Developments
- Shionogi Co.
- Shionogi Co. Comapny Information
- Shionogi Co. Business Overview
- Shionogi Co. Peramivir Sales, Value and Gross Margin (2020-2025)
- Shionogi Co. Peramivir Product Portfolio
- Shionogi Co. Recent Developments
- BioCryst Pharmaceuticals
- Value Chain and Sales Channels Analysis
- Peramivir Value Chain Analysis
- Peramivir Key Raw Materials
- Raw Materials Key Suppliers
- Manufacturing Cost Structure
- Peramivir Sales Mode & Process
- Peramivir Sales Channels Analysis
- Direct Comparison with Distribution Share
- Peramivir Distributors
- Peramivir Customers
- Peramivir Value Chain Analysis
- Concluding Insights
- Appendix
- Reasons for Doing This Study
- Research Methodology
- Research Process
- Authors List of This Report
- Data Source
- Secondary Sources
- Primary Sources
List of Tables
Table 1 | :Peramivir Industry Trends |
Table 2 | :Peramivir Industry Drivers |
Table 3 | :Peramivir Industry Opportunities and Challenges |
Table 4 | :Peramivir Industry Restraints |
Table 5 | :Global Peramivir Revenue by Company (US$ Million) & (2020-2025) |
Table 6 | :Global Peramivir Revenue Share by Company (2020-2025) |
Table 7 | :Global Peramivir Sales Volume by Company (Tons) & (2020-2025) |
Table 8 | :Global Peramivir Sales Volume Share by Company (2020-2025) |
Table 9 | :Global Peramivir Average Price (US$/Kg) of Company (2020-2025) |
Table 10 | :Global Peramivir Company Ranking, (2023-2025) & (USD Million) |
Table 11 | :Global Peramivir Key Company Manufacturing Base & Headquarters |
Table 12 | :Global Peramivir Company, Product Type & Application |
Table 13 | :Global Peramivir Company Establishment Date |
Table 14 | :Global Company Market Concentration Ratio (CR5 and HHI) |
Table 15 | :Global Peramivir by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2024) |
Table 16 | :Mergers & Acquisitions, Expansion |
Table 17 | :Significant Companies of Solution |
Table 18 | :Significant Companies of Solid |
Table 19 | :Global Peramivir Sales Volume by Type 2020 VS 2024 VS 2031 (Tons) |
Table 20 | :Global Peramivir Sales Volume by Type (2020-2025) & (Tons) |
Table 21 | :Global Peramivir Sales Volume by Type (2026-2031) & (Tons) |
Table 22 | :Global Peramivir Sales Volume Share by Type (2020-2025) |
Table 23 | :Global Peramivir Sales Volume Share by Type (2026-2031) |
Table 24 | :Global Peramivir Sales Value by Type 2020 VS 2024 VS 2031 (US$ Million) |
Table 25 | :Global Peramivir Sales Value by Type (2020-2025) & (US$ Million) |
Table 26 | :Global Peramivir Sales Value by Type (2026-2031) & (US$ Million) |
Table 27 | :Global Peramivir Sales Value Share by Type (2020-2025) |
Table 28 | :Global Peramivir Sales Value Share by Type (2026-2031) |
Table 29 | :Significant Companies of Influenza A Treatment |
Table 30 | :Significant Companies of Influenza B Treatment |
Table 31 | :Global Peramivir Sales Volume by Application 2020 VS 2024 VS 2031 (Tons) |
Table 32 | :Global Peramivir Sales Volume by Application (2020-2025) & (Tons) |
Table 33 | :Global Peramivir Sales Volume by Application (2026-2031) & (Tons) |
Table 34 | :Global Peramivir Sales Volume Share by Application (2020-2025) |
Table 35 | :Global Peramivir Sales Volume Share by Application (2026-2031) |
Table 36 | :Global Peramivir Sales Value by Application 2020 VS 2024 VS 2031 (US$ Million) |
Table 37 | :Global Peramivir Sales Value by Application (2020-2025) & (US$ Million) |
Table 38 | :Global Peramivir Sales Value by Application (2026-2031) & (US$ Million) |
Table 39 | :Global Peramivir Sales Value Share by Application (2020-2025) |
Table 40 | :Global Peramivir Sales Value Share by Application (2026-2031) |
Table 41 | :Global Peramivir Sales by Region: 2020 VS 2024 VS 2031 (Tons) |
Table 42 | :Global Peramivir Sales by Region (2020-2025) & (Tons) |
Table 43 | :Global Peramivir Sales Market Share by Region (2020-2025) |
Table 44 | :Global Peramivir Sales by Region (2026-2031) & (Tons) |
Table 45 | :Global Peramivir Sales Market Share by Region (2026-2031) |
Table 46 | :Global Peramivir Sales Value Comparison by Region: 2020 VS 2024 VS 2031 (US$ Million) |
Table 47 | :Global Peramivir Sales Value by Region (2020-2025) & (US$ Million) |
Table 48 | :Global Peramivir Sales Value Share by Region (2020-2025) |
Table 49 | :Global Peramivir Sales Value by Region (2026-2031) & (US$ Million) |
Table 50 | :Global Peramivir Sales Value Share by Region (2026-2031) |
Table 51 | :Global Peramivir Market Average Price (US$/Kg) by Region (2020-2025) |
Table 52 | :Global Peramivir Market Average Price (US$/Kg) by Region (2026-2031) |
Table 53 | :Global Peramivir Sales by Country: 2020 VS 2024 VS 2031 (Tons) |
Table 54 | :Global Peramivir Sales Value by Country: 2020 VS 2024 VS 2031 (US$ Million) |
Table 55 | :Global Peramivir Sales by Country (2020-2025) & (Tons) |
Table 56 | :Global Peramivir Sales Market Share by Country (2020-2025) |
Table 57 | :Global Peramivir Sales by Country (2026-2031) & (Tons) |
Table 58 | :Global Peramivir Sales Market Share by Country (2026-2031) |
Table 59 | :Global Peramivir Sales Value by Country (2020-2025) & (US$ Million) |
Table 60 | :Global Peramivir Sales Value Market Share by Country (2020-2025) |
Table 61 | :Global Peramivir Sales Value by Country (2026-2031) & (US$ Million) |
Table 62 | :Global Peramivir Sales Value Market Share by Country (2026-2031) |
Table 63 | :BioCryst Pharmaceuticals Company Information |
Table 64 | :BioCryst Pharmaceuticals Business Overview |
Table 65 | :BioCryst Pharmaceuticals Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025) |
Table 66 | :BioCryst Pharmaceuticals Peramivir Product Portfolio |
Table 67 | :BioCryst Pharmaceuticals Recent Development |
Table 68 | :Green Cross Pharma Company Information |
Table 69 | :Green Cross Pharma Business Overview |
Table 70 | :Green Cross Pharma Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025) |
Table 71 | :Green Cross Pharma Peramivir Product Portfolio |
Table 72 | :Green Cross Pharma Recent Development |
Table 73 | :Hikma Pharmaceuticals Company Information |
Table 74 | :Hikma Pharmaceuticals Business Overview |
Table 75 | :Hikma Pharmaceuticals Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025) |
Table 76 | :Hikma Pharmaceuticals Peramivir Product Portfolio |
Table 77 | :Hikma Pharmaceuticals Recent Development |
Table 78 | :Moksha8 Pharma Company Information |
Table 79 | :Moksha8 Pharma Business Overview |
Table 80 | :Moksha8 Pharma Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025) |
Table 81 | :Moksha8 Pharma Peramivir Product Portfolio |
Table 82 | :Moksha8 Pharma Recent Development |
Table 83 | :NeoPharm Company Information |
Table 84 | :NeoPharm Business Overview |
Table 85 | :NeoPharm Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025) |
Table 86 | :NeoPharm Peramivir Product Portfolio |
Table 87 | :NeoPharm Recent Development |
Table 88 | :NT Pharma Company Information |
Table 89 | :NT Pharma Business Overview |
Table 90 | :NT Pharma Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025) |
Table 91 | :NT Pharma Peramivir Product Portfolio |
Table 92 | :NT Pharma Recent Development |
Table 93 | :SCOLR Pharma Company Information |
Table 94 | :SCOLR Pharma Business Overview |
Table 95 | :SCOLR Pharma Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025) |
Table 96 | :SCOLR Pharma Peramivir Product Portfolio |
Table 97 | :SCOLR Pharma Recent Development |
Table 98 | :Hunan Nucien Pharmaceutical Co., Ltd. Company Information |
Table 99 | :Hunan Nucien Pharmaceutical Co., Ltd. Business Overview |
Table 100 | :Hunan Nucien Pharmaceutical Co., Ltd. Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025) |
Table 101 | :Hunan Nucien Pharmaceutical Co., Ltd. Peramivir Product Portfolio |
Table 102 | :Hunan Nucien Pharmaceutical Co., Ltd. Recent Development |
Table 103 | :Merck Company Information |
Table 104 | :Merck Business Overview |
Table 105 | :Merck Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025) |
Table 106 | :Merck Peramivir Product Portfolio |
Table 107 | :Merck Recent Development |
Table 108 | :Shionogi Co. Company Information |
Table 109 | :Shionogi Co. Business Overview |
Table 110 | :Shionogi Co. Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025) |
Table 111 | :Shionogi Co. Peramivir Product Portfolio |
Table 112 | :Shionogi Co. Recent Development |
Table 113 | :Key Raw Materials |
Table 114 | :Raw Materials Key Suppliers |
Table 115 | :Peramivir Distributors List |
Table 116 | :Peramivir Customers List |
Table 117 | :Research Programs/Design for This Report |
Table 118 | :Authors List of This Report |
Table 119 | :Secondary Sources |
Table 120 | :Primary Sources |
List of Figures
Figure 1 | :Peramivir Product Image |
Figure 2 | :Global Peramivir Sales Value (US$ Million), 2020 VS 2024 VS 2031 |
Figure 3 | :Global Peramivir Sales Value (2020-2031) & (US$ Million) |
Figure 4 | :Global Peramivir Sales (2020-2031) & (Tons) |
Figure 5 | :Global Peramivir Sales Average Price (US$/Kg) & (2020-2031) |
Figure 6 | :Global Peramivir Company Revenue Ranking in 2024 (US$ Million) |
Figure 7 | :Global Top 5 and 10 Company Market Share by Revenue in 2024 (US$ Million) |
Figure 8 | :Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024 |
Figure 9 | :Solution Image |
Figure 10 | :Solid Image |
Figure 11 | :Global Peramivir Sales Volume by Type (2020 VS 2024 VS 2031) & (Tons) |
Figure 12 | :Global Peramivir Sales Volume Share 2020 VS 2024 VS 2031 |
Figure 13 | :Global Peramivir Sales Volume Share by Type (2020-2031) |
Figure 14 | :Global Peramivir Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million) |
Figure 15 | :Global Peramivir Sales Value Share 2020 VS 2024 VS 2031 |
Figure 16 | :Global Peramivir Sales Value Share by Type (2020-2031) |
Figure 17 | :Influenza A Treatment Image |
Figure 18 | :Influenza B Treatment Image |
Figure 19 | :Global Peramivir Sales Volume by Application (2020 VS 2024 VS 2031) & (Tons) |
Figure 20 | :Global Peramivir Sales Volume Share 2020 VS 2024 VS 2031 |
Figure 21 | :Global Peramivir Sales Volume Share by Application (2020-2031) |
Figure 22 | :Global Peramivir Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million) |
Figure 23 | :Global Peramivir Sales Value Share 2020 VS 2024 VS 2031 |
Figure 24 | :Global Peramivir Sales Value Share by Application (2020-2031) |
Figure 25 | :Global Peramivir Sales by Region: 2020 VS 2024 VS 2031 (Tons) |
Figure 26 | :Global Peramivir Sales Market Share by Region: 2020 VS 2024 VS 2031 |
Figure 27 | :Global Peramivir Sales Value Comparison by Region: 2020 VS 2024 VS 2031 (US$ Million) |
Figure 28 | :Global Peramivir Sales Value Share by Region: 2020 VS 2024 VS 2031 |
Figure 29 | :North America Peramivir Sales Value (2020-2031) & (US$ Million) |
Figure 30 | :North America Peramivir Sales Value Share by Country (%), 2024 VS 2031 |
Figure 31 | :Europe Peramivir Sales Value (2020-2031) & (US$ Million) |
Figure 32 | :Europe Peramivir Sales Value Share by Country (%), 2024 VS 2031 |
Figure 33 | :Asia-Pacific Peramivir Sales Value (2020-2031) & (US$ Million) |
Figure 34 | :Asia-Pacific Peramivir Sales Value Share by Country (%), 2024 VS 2031 |
Figure 35 | :South America Peramivir Sales Value (2020-2031) & (US$ Million) |
Figure 36 | :South America Peramivir Sales Value Share by Country (%), 2024 VS 2031 |
Figure 37 | :Middle East & Africa Peramivir Sales Value (2020-2031) & (US$ Million) |
Figure 38 | :Middle East & Africa Peramivir Sales Value Share by Country (%), 2024 VS 2031 |
Figure 39 | :USA Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 40 | :USA Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 41 | :USA Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 42 | :Canada Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 43 | :Canada Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 44 | :Canada Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 45 | :Mexico Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 46 | :Mexico Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 47 | :Mexico Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 48 | :Germany Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 49 | :Germany Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 50 | :Germany Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 51 | :France Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 52 | :France Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 53 | :France Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 54 | :U.K. Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 55 | :U.K. Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 56 | :U.K. Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 57 | :Italy Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 58 | :Italy Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 59 | :Italy Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 60 | :Spain Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 61 | :Spain Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 62 | :Spain Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 63 | :Russia Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 64 | :Russia Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 65 | :Russia Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 66 | :Netherlands Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 67 | :Netherlands Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 68 | :Netherlands Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 69 | :Nordic Countries Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 70 | :Nordic Countries Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 71 | :Nordic Countries Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 72 | :China Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 73 | :China Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 74 | :China Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 75 | :Japan Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 76 | :Japan Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 77 | :Japan Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 78 | :South Korea Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 79 | :South Korea Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 80 | :South Korea Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 81 | :India Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 82 | :India Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 83 | :India Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 84 | :Australia Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 85 | :Australia Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 86 | :Australia Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 87 | :Southeast Asia Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 88 | :Southeast Asia Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 89 | :Southeast Asia Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 90 | :Brazil Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 91 | :Brazil Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 92 | :Brazil Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 93 | :Argentina Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 94 | :Argentina Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 95 | :Argentina Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 96 | :Chile Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 97 | :Chile Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 98 | :Chile Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 99 | :Colombia Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 100 | :Colombia Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 101 | :Colombia Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 102 | :Peru Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 103 | :Peru Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 104 | :Peru Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 105 | :Saudi Arabia Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 106 | :Saudi Arabia Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 107 | :Saudi Arabia Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 108 | :Israel Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 109 | :Israel Arabia Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 110 | :Israel Arabia Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 111 | :UAE Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 112 | :UAE Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 113 | :UAE Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 114 | :Turkey Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 115 | :Turkey Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 116 | :Turkey Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 117 | :Iran Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 118 | :Iran Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 119 | :Iran Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 120 | :Egypt Peramivir Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 121 | :Egypt Peramivir Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 122 | :Egypt Peramivir Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 123 | :Peramivir Value Chain |
Figure 124 | :Manufacturing Cost Structure |
Figure 125 | :Peramivir Sales Mode & Process |
Figure 126 | :Direct Comparison with Distribution Share |
Figure 127 | :Distributors Profiles |
Figure 128 | :Years Considered |
Figure 129 | :Research Process |
Figure 130 | :Key Executives Interviewed |
Request a Sample
Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Pharma & Healthcare
Global Peramivir Market Outlook and Growth Opportunities 2025
Pages: 194
Complete Your Request
Customer reviews
- 0 out of 5
- 0 Reviews
5
4
3
2
1
No Rating Review Exist.
Write Review
Suggested Report
View MoreNo data found.